Evidence map›Paper›PMID 40558477›Full record

ReviewBiosensors2025

Advances in Research on Isothermal Signal Amplification Mediated MicroRNA Detection of Clinical Samples: Application to Disease Diagnosis.

Yu Han, Xin Sun, Sheng Cai

Abstract readReview
In one paragraph

Review in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yu HanSchool of Pharmaceutical Sciences, Jilin Medical University, Jilin 132013, China.ORCID 0000-0002-2390-6257
Xin SunSchool of Pharmaceutical Sciences, Jilin Medical University, Jilin 132013, China.ORCID 0000-0001-8891-156X
Sheng CaiZhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.ORCID 0000-0002-0876-0050

Funding

Jilin Medical University JYBS2023005LK
6 · The paper itself

Abstract

With the rapid development of modern molecular biology, microRNA (miRNA) has been demonstrated to be closely associated with the occurrence and development of tumors and holds significant promise as a biomarker for the early detection, diagnosis, and treatment of cancer and other diseases. Therefore, detecting miRNA and analyzing it to determine its biological functions are of great significance for the screening and diagnosis of diseases. However, the intrinsic characteristics of miRNAs, including their low abundance, short sequence lengths, and high family-specific sequence homology, render traditional detection methods such as Northern blot hybridization, microarray use, and reverse transcription quantitative PCR (RT-qPCR) inadequate for meeting the stringent requirements of clinical detection in biological samples, a task requiring accuracy, rapidity, high detection power, specificity, and cost-effectiveness. In recent years, a substantial amount of effort has been put into developing innovative methodologies to address these challenges. In this review, we aim to provide a comprehensive overview of the recent advancements in these methodologies and their applications in clinical biological sample detection for disease diagnosis.

Indexed as

Biosensing TechniquesMicroRNAsNucleic Acid Amplification TechniquesHumansNeoplasmsMicroRNAsdisease diagnosisisothermal signal amplificationmiRNA detectionpoint-of-care testing

Identifiers

PMID40558477
PMCPMC12190449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.